<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652327</url>
  </required_header>
  <id_info>
    <org_study_id>P04355</org_study_id>
    <nct_id>NCT00652327</nct_id>
  </id_info>
  <brief_title>Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)</brief_title>
  <official_title>A Multicenter, Randomized, Open-labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety and Tolerability of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Ongoing Statin in the Treatment of Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, parallel group comparison study. Following a 1-week
      screening period, patients will be randomized to 1 of 2 treatment groups: ezetimibe added to
      ongoing statin treatment (ezetimibe plus simvastatin, atorvastatin or pravastatin at doses of
      10/20, 10/10 or 10/20 mg), or doubling the dose of ongoing statin (simvastatin 40 mg,
      atorvastatin 20 mg, or pravastatin 40 mg). Study drug will be administered once daily in the
      evening for 8 weeks. Patients will be instructed to follow a National Cholesterol Education
      Program (NCEP) or similar cholesterol-lowering dietary regimen throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment</measure>
    <time_frame>Assessed at the end of 8 weeks of treatment (from baseline to endpoint)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)</intervention_name>
    <description>ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks</description>
    <arm_group_label>Ezetimibe + Statin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double Statin (simvastatin, atorvastatin, or pravastatin)</intervention_name>
    <description>simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks</description>
    <arm_group_label>Double Statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        80-120 patients will be recruited in this study. All patients must meet the following
        criteria and follow an NCEP or similar cholesterol-lowering dietary regimen throughout the
        study:

          -  Men or women ≧18 and ≦80 years of age (Female patients receiving hormone therapy
             [including hormone replacement therapy, and estrogen antagonist/agonist, or oral
             contraceptives] and maintained on a stable dose and regimen for at least 8 weeks prior
             to visit 1 must be willing to continue the same regimen throughout the study. Females
             of childbearing potential must be using a medically acceptable method of birth
             control).

          -  Willing to follow an NCEP Therapeutic Lifestyle Changes (TLC) or similar
             cholesterol-lowering diet for the duration of the study.

          -  Patients with hypercholesterolemia who cannot achieve the optimal therapeutic goal
             with previous statin treatment (simvastatin 20 mg, atorvastatin 10 mg or pravastatin
             20 mg alone for at least 12 weeks) will be enrolled into study. The treatment goal in
             primary prevention is LDL-C ＜160 mg/dL or LDL-C ＜130 mg/dL patient with ≧ 2 risk
             factors (risk factors: hypertension, male ≧ 45 years old, family of premature coronary
             artery disease [CAD], female ≧ 55 years old or menopause without hormone replace
             therapy, smoking); LDL-C ≤ 100 mg/dL in CAD patients (documented by coronary
             angiogram, positive treadmill test or thallium scan), or diabetes mellitus (DM)
             patients (Ante Cibum [AC][fasting plasma glucose] &gt;126 mg/dL, Post Cibum [PC] [oral
             glucose tolerance test] &gt; 200 mg/dL, World Health Organization criteria), ischemic
             stroke (neurological dysfunction with documented diagnosis with computed tomography
             [CT] or magnetic resonance imaging [MRI]), peripheral artery disease.

          -  Triglyceride (TG) concentrations ≦ 400 mg/dL.

          -  Liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase
             [AST]) ≦ 2 x upper limit of normal (ULN) with no active liver disease and creatine
             kinase (CK) ≦ 2 x ULN at screen visit.

        Exclusion Criteria:

        The following conditions preclude patients from entry into this study:

          -  Women who are pregnant or lactating.

          -  History of mental instability, drug/alcohol abuse within the past 5 years, or major
             psychiatric illness not adequately controlled and stable on pharmacotherapy

          -  Patients who have been treated with any other investigational drug within 3 months of
             visit 1.

          -  Patients previously randomized to a study with ezetimibe.

          -  Active liver disease or Impaired liver function tests (ALT, AST &gt; 2xULN).

          -  Impaired renal function ( serum creatinine ≧1.5 mg/dL) or nephrotic syndrome at visit
             1

          -  Unstable angina

          -  Acute myocardial infarction, coronary bypass surgery within the previous six months of
             visit 1.

          -  Uncontrolled cardiac arrhythmias

          -  Uncontrolled hypertension (treated or untreated) with systolic blood pressure &gt; 160
             mmHg or diastolic &gt; 100 mmHg at visit 1.

          -  Poorly controlled diabetes mellitus patient (Patients who are under insulin injection
             and HbA1c&gt;10.0%). If the patient is treated with medication for diabetes, the
             medication will be unchanged during the study period.

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoprotein, e.g. hypothyroidism (thyroid-stimulating hormone [TSH] &gt; 5.5 uIU/mL).
             However, patients who are on a stable therapy of thyroid replacement therapy for at
             least 6 weeks are eligible for enrollment.

          -  Patients hypersensitive to HMG-CoA reductase inhibitors or ezetimibe.

          -  Patient who is unable to give informed consent (the patient with a legal
             representative to sign the informed consent is eligible to participate the study).

          -  Any condition or situation which, in the opinion of the investigator, might pose a
             risk to the patient or confound the results of the study.

          -  Prohibited concomitant therapies.

               -  Medications that are potent inhibitors of CYP3A4, including cyclosporine,
                  systemic itraconazole or ketoconazole, erythromycin or clarithromycin,
                  nefazodone, verapamil and human immunodeficiency virus (HIV) protease inhibitors.

               -  Lipid-lowering agents including fish oils, Cholestin, bile-acid sequestrants, and
                  niacin (&lt;200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks prior
                  to enrollment.

               -  Oral corticosteroids unless used as replacement therapy for pituitary/adrenal
                  disease and treated with a stable regimen for at least 6 weeks prior to
                  enrollment.

               -  Treatment with psylium, other fiber-based laxatives, and/or over-the-counter
                  (OTC) therapies known to affect serum lipid levels, phytosterol margarines,
                  unless treated with a stable regimen for at least 6 weeks prior to enrollment,
                  and patient agrees to remain on constant regimen for the duration of the study.

          -  Patient is consuming &gt; 250 ml of grapefruit juice per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <results_first_submitted>May 12, 2010</results_first_submitted>
  <results_first_submitted_qc>May 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2010</results_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 202 potential participants signed informed consent during a screening visit. Of these, 119 did not meet protocol eligibility requirements. The remainder, 83, received randomized treatment assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe + Statin</title>
          <description>Once daily 10-mg ezetimibe tablet added to daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Double Statin</title>
          <description>Double the dose of daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42">Participants who recieved randomized treatment assignment to ezetimibe and ongoing statin</participants>
                <participants group_id="P2" count="41">Participants who recieved randomized treatment assignment to double the dose of ongoing statin</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe + Statin</title>
          <description>Once daily 10-mg ezetimibe tablet added to daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Double Statin</title>
          <description>Double the dose of daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 83 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=83 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan, Province Of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment</title>
        <time_frame>Assessed at the end of 8 weeks of treatment (from baseline to endpoint)</time_frame>
        <population>The population analyzed (intent-to-treat [ITT]) included all participants who had a post-randomization LDL-C laboratory evaluation. As such, 20 of the 83 participants who received treatment assignment were excluded from the ITT. The 5 participants who discontinued were included in the ITT as each had a post-randomization LDL-C lab evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Statin</title>
            <description>Once daily 10-mg ezetimibe tablet added to daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Double Statin</title>
            <description>Double the dose of daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment</title>
          <population>The population analyzed (intent-to-treat [ITT]) included all participants who had a post-randomization LDL-C laboratory evaluation. As such, 20 of the 83 participants who received treatment assignment were excluded from the ITT. The 5 participants who discontinued were included in the ITT as each had a post-randomization LDL-C lab evaluation.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.56" spread="19.78"/>
                    <measurement group_id="O2" value="-9.7" spread="21.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0026</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe + Statin</title>
          <description>Once daily 10-mg ezetimibe tablet added to daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Double Statin</title>
          <description>Double the dose of daily ongoing statin treatment (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

